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Abstract
Background: Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the
Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the
neurological symptoms that characterize this syndrome. Nevertheless, the molecular mechanism underlying the
glucocorticoid action in AT patients is not yet understood. Recently, we have demonstrated that Dexamethasone
treatment may partly restore ATM activity in AT lymphoblastoid cells by a new ATM transcript, namely ATMdexa1.
Results: In the present study, the new ATMdexa1 transcript was also identified in vivo, specifically in the PMBCs of
AT patients treated with intra-erythrocyte Dexamethasone (EryDex). In these patients it was also possible to isolate
new “ATMdexa1 variants” originating from canonical and non-canonical splicing, each containing the coding sequence
for the ATM kinase domain. The expression of the ATMdexa1 transcript family was directly related to treatment and
higher expression levels of the transcript in patients’ blood correlated with a positive response to Dexamethasone
therapy. Neither untreated AT patients nor untreated healthy volunteers possessed detectable levels of the transcripts.
ATMdexa1 transcript expression was found to be elevated 8 days after the drug infusion, while it decreased 21 days
after treatment.
Conclusions: For the first time, the expression of ATM splicing variants, similar to those previously observed in vitro,
has been found in the PBMCs of patients treated with EryDex. These findings show a correlation between the
expression of ATMdexa1 transcripts and the clinical response to low dose dexamethasone administration.
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Background
In the last few years, experimental investigations and clin-
ical trials have provided evidence that short-term treatment
with glucocorticoid (GC) analogues is able to improve
neurological symptoms in AT patients [1–4] raising the
possibility that cerebellar abnormalities may still be modi-
fied during the initial phase of cell loss [5]. However, this
neurological improvement is transitory and disappears
when oral GC administration is discontinued, and the
benefit-to-risk balance limits the long-term administration
of oral steroids.
The administration of low doses of GC through autolo-
gous erythrocytes could reduce steroid toxicity without
affecting drug efficacy [6–9] . Indeed, a phase II clinical
study IEDAT (EudraCT Number 2010–022315-19, a 6-
month single-arm open labeled trial), which envisaged the
long-term treatment of AT patients with intra-erythrocyte
Dexamethasone (Dexa), has recently been concluded [10].
The treatment led to a significant improvement in
neurological symptoms, while at the same time avoiding
typical steroid side effects. However, the specific mecha-
nisms underlying the action of dexamethasone in the treat-
ment of the neurodegenerative disease are still under
debate [11, 12]. The Ataxia Telangiectasia-Mutated (ATM)
gene was first described by Savitsky K, et al. [13]. This gene,
which codifies for a protein kinase member of the PI3
Kinase-like Kinase (PIKK) family, is transcribed into 27 dif-
ferent mRNAs, 20 alternatively spliced variants and 7
unspliced forms. Eighteen spliced mRNAs putatively encode
good proteins, while the remaining 9 mRNA variants appear
not to encode good proteins. (Aceview https://
www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html).
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In a recent investigation using lymphoblastoid cell lines
(LCLs) derived from AT patients as a model, we showed
that the action of glucocorticoids may stem from the
prompting of a non-canonical splicing event in the ATM
mRNA precursor [14]. Specifically, we were able to identify
a transcript of 1582 bp called ATMdexa1.
The main aim of the present study was to investigate the
possible presence of ATMdexa1 in the blood cells of pa-
tients enrolled in the above-mentioned IEDAT clinical trial.
In fact, we were not only able to identify the transcript,
whose expression depends on drug administration, but also
to show that it can act as a blood molecular marker to
gauge therapy responsiveness. Interestingly, in treated pa-
tients it was also possible to discover several additional
ATMdexa1 variants.
Methods
Sample collection, RNA extraction and complementary
cDNA synthesis
The blood samples were collected from 10 AT patients
(6 males and 4 females, average age 9.7 years) enrolled
in the IEDAT clinical trial (IEDAT-ERY01–2010) [10],
from 6 untreated AT patients (4 females and 2 males,
average age 17.5 years) and 6 untreated healthy volun-
teers (childhood blood samples, unknown gender). For
all the treated patients, blood was drawn 21 days after
drug administration, and for 2 of those patients, it was
also drawn 8 days after treatment administration.
Blood samples were also collected from 5 AT partici-
pants (4 females and one male, average age 12.1 years)
that were treated with EryDex (compassionate use).
Briefly, 3 ml of blood were collected in appropriate
vacutainers (Tempus Blood RNA tubes, Life Technologies)
and handled and stored according to the manufacturer’s
instructions The blood samples were subsequently proc-
essed for total RNA extraction using the Tempus spin RNA
isolation kit (Life Technologies) as described in the manu-
facturer’s instructions. A clean-up was performed using the
QIAGEN RNA extraction kit to completely eliminate con-
taminating DNA. For each sample, 500 ng of RNA was
employed as a template for cDNA synthesis using the
SMARTScribe Reverse Transcriptase (Takara) in the pres-
ence of 50 ng of Random hexamers to prime the reaction.
Quantitative PCR assays
Two qPCR assays were set up for ATMdexa1 estimation.
All PCR reactions were carried out using the ABI PRISM
7500 sequence detection system platform (Applied
Biosystems). The first assay was based on SYBR green
chemistry by SYBR Premix Ex Taq (Tli RNaseH Plus
Takara), with a final amount of MgCl2 3.5 mM, and
300 nM of each primer (Forward 5′-ATCTAGATCGG
CATTCAGATTCCA-3′ and Reverse 5′-GCAGACCAGC
CAATTACTAAAC-3′). The thermal profile optimized to
obtain a specific and linear amplification of ATMdexa1 was
set for 30 s at 95 °C, followed by 40 cycles of denaturation
(for 10 s at 94 °C), annealing (for 20 s at 65 °C) and exten-
sion at 72 °C for 40 s. A melting curve analysis of the
amplicons was performed at the end of each reaction.
The second analysis consisted of a 5′ exonuclease-based
real-time PCR assay performed with the same primers de-
scribed above with the addition of 100 nM of the ATM-
dexa1 probe (5′6-FAM ATGCCACTCAGTGGAAGACT
CAGAGAA-BHQ1 3′); the PCR reaction was performed
using the Hot-Rescue Real-Time PCR Kit–FP (Diatheva).
The thermal profile was performed for 30 s at 95 °C,
followed by 40 10-s. cycles at 94 °C and annealing/ exten-
sion at 72 °C for 60 s. The FKBP5 and DUSP1 gene expres-
sion levels were measured using the TaqMan® Gene
Expression Assays kit (Life Technologies) according to the
manufacturer’s instructions.
Concomitantly with the targets, the cDNA of HPRT1
was amplified using 5′-TATGCTGAGGATTTGGAAAG
GGT-3′ and 5′-CCATCACATTGTAGCCCTCT-3′ as
upper and lower primers, respectively. In the 5′ exo-
nuclease qPCR, the 5′-JOE-TATGGACAGGACT
GAACGTCTTGC-BHQ1–3′ probe was used and the
reactions were also achieved in multiplex mode. The
relative quantification of the targets was calculated by
the ΔCT method [15] (HPRT1 as reference gene) and
plotted as 1/2ΔCT.
Results
Following approval by the ethical committees and the
patients or their parents, blood samples of 10 out of 22
patients enrolled in the IEDAT clinical study were ob-
tained. Blood collection was carried out at the end of the
treatment, precisely 21 days after the sixth and final in-
fusion of intra-erythrocitary Dexamethasone provided in
the clinical study.
The qPCR assays were set up for qualitative and quan-
titative analysis, to identify the mRNA molecule,
previously described in lymphoblastoid cell lines. The
assays were validated in terms of efficiency and Target to
Reference linearity (not shown).
ATMdexa1 PCR amplification was carried out in all the
10 IEDAT available samples and also in 6 untreated AT
patients and in 6 untreated healthy volunteers. Specific
amplification of the target was obtained only in IEDAT
samples, while in untreated AT patients and healthy con-
trols, the expression levels were undetectable (Fig. 1a).
The amplification carried out by SYBR green PCR on
blood samples was similar to those obtained during the
assay setup, but a small melting curve deviation was ob-
served among the samples (Additional file 1: Fig. S1). The
results obtained using the SYBR green PCR were con-
firmed by a 5′ nuclease assay as illustrated in Fig. 1b.
These results suggest that the induction of the ATMdexa1
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RNA messenger is limited to AT patients and strictly
dependent on treatment with the drug. The efficacy of
EryDex in treating neurological symptoms of AT patients
has been evaluated using the ICARS scale [16], and im-
provements were found to be related to the drug encapsu-
lation efficiency, and therefore to the quantity of the drug
administrated [10]. Hence, a direct relationship between
drug encapsulation efficiency and ATMdexa1 expression
for the 10 available values was tested but the correlation
was found to be poor.
In the same previous study by Chessa et al. [10] patients
were clustered as either responders or non-responders
(AT Dexa R and NR). Responders (ΔICARS ≥ −10) were
designated as loaders (Dexa ≥5 mg/bag), while the non-
responders (ΔICARS ≤ −9) were designated as poor loaders
(Dexa ≤4.9 mg/bag). In the present investigation we were
also able to cluster the 10 AT participants into responder (5
AT Dexa R) or non-responder groups (5 AT Dexa NR) using
the ΔICARS score. Likewise, the matching ATMdexa1 ex-
pression data were assigned to the two clusters. Interestingly,
the responders showed a statistically greater ATMdexa1 ex-
pression (t-test p = 0.0425) than did non-responders (Fig. 2a).
Furthermore, for one responder and one non-responder, it was
possible to evaluate the ATMdexa1 expression in blood sam-
ples collected at +8 and +21 days from EryDex administra-
tion. In this case as well the responder showed higher
expression levels than those of the non-responder at both
times (Fig. 2b). Moreover, by comparing intra-patient levels,
it was observed that the ATMdexa1 transcript was expressed
at greater levels at +8 day than it was at +21 day. This is
consistent with the gradual waning of the DEXA effect over
time after treatment, and underlines the need to resort to
Fig. 1 ATMdexa1 expression levels in patients treated with EryDex.
Two qPCR assays were set up for ATMdexa1 estimation in whole
blood. AT, untreated patients with AT n = 6; AT Dexa, patients with
AT and treated with EryDex n = 10; WT, healthy volunteers n = 6.
The first qPCR assay is based on SYBR green chemistry PCR (panel a)
while a second one is built on 5′ exonuclease qPCR (panel b). In
both settings, ATMdexa1 expression levels were detectable only in
AT patients treated with EryDex. The transcript was undetectable in
untreated AT patients and in healthy volunteers
Fig. 2 ATMdexa1 expression in responders and non-responders. In
panel a, AT patients treated with EryDex were divided into two
clusters (responders R n = 5 and non-responders NR n = 5, by
average ICARS value decrement of at least 10 points, after six
months of therapy). Responders showed higher levels of ATMdexa1
expression (p < 0.05) than did non-responders. In panel b, for one
patient from each cluster, it was possible to evaluate the expression
of ATMdexa1 also at +8 days from EryDex administration. In both
cases, the extent of the target expression was time dependent
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repeated administrations in order to keep the drug effective-
ness active. In order to assess if the improvement in respon-
siveness depended on glucocorticoid sensitivity the gene
expression of two targets (FKBP5 and DUSP1), known to be
glucocorticoids modulated [17, 18], were tested (Fig. 3). As
expected, the average expression levels of both targets were
found to be more elevated than those found in untreated
subjects, but not statistically different in the two groups of
patients (R and NR).
The samples from patients treated with EryDex (compas-
sionate usage), allowed a deeper analysis of amplicons
obtained by qPCR assays. In these samples the ATMdexa1
was also detected and in order to verify the small
temperature deviance observed during the qPCR melting
step, as mentioned above, the amplicons were checked by
gel electrophoresis. In Fig. 4 lanes 1–16 contain the qPCR
products from 5 patient samples collected at different time
points. The miniATM PCR product is indicated by white
arrows, while the other bands represent unattended ampli-
cons. After the cloning and the DNA sequencing of some
of the PCR products, it was possible to define five (cur-
rently) new ATM transcripts designated as “ATMdexa1
variants” (Fig. 4 coloured arrows). Every variant contained
the qPCR assay probe domain and possessed the coding se-
quence for the kinase domain of the ATM native protein
(Fig. 5). Three of the variants derived from the canonical
splicing of the ATM mRNA (exons 3–52, 4–53 and 2–52),
whereas two variants originated from a SDR (short direct
repeat: 3–52 and 4–51) mediated splicing process. The
amplicon size differences from ATMdexa1 ranged from ap-
proximately 50 to 160 bp. Some of the described amplicons
might explain the observed melting analysis discrepancies
during the above-mentioned SYBR green qPCR tests.
Samples from dissimilar patients or from the same patients,
but at different blood collection times, showed indistinctly
variegated ATMdexa1 variants and sometimes even more
than one simultaneously (Fig. 4). All the ATMdexa1variants
possess the MetMet starting site described by Menotta
et al. [14] and can be translated in the miniATM protein by
conceptual translation.
Discussion
In recent years, observational studies and a few clinical
trials have shown that short-term treatment of AT patients
with oral glucocorticoids is able to improve their
neurological symptoms [1–5]. Unfortunately, this improve-
ment is merely transitory and fades shortly after discontinu-
ation of oral treatment with GC. Suspension of the GC
treatment is necessary since the hazards long-term therapy
with steroids outweigh any potential benefits such a therapy
may confer [11]. To overcome this limitation the
administration of very low GC doses by erythrocytes
reduces steroid toxicity without compromising the drug’s
effectiveness [6–9].
In 2010 a phase II clinical study, envisaging the long-
term treatment of AT patients by Dexa encapsulated
within autologous erythrocytes, was set up [10, 19]. The
proposed therapy brought about a significant improve-
ment in neurological symptoms, while avoiding the
onset of known side effects typical of GC. Although the
mechanism of action of glucocorticoids in AT patients
remains unclear, over the past few years several studies
have been conducted to shed light on mechanisms
underlying the effects of GC in AT patients. D’Assante
et al. reported the influence of Betamethasone on mole-
cules involved in autophagosome degradation [20], while
the authors of the present study described the influence
of Dexamethasone on gene expression, NRF2-mediated
antioxidant response by redox balance improvement and
cellular nano-mechanics by cytoskeleton and nuclear dy-
namics [21–23]. Furthermore, despite the observation
Fig. 3 FKBP5 and DUSP1 mRNA expression. Gene expression levels
of the two evaluated prototypic targets. AT, untreated patients with
AT n = 6; AT Dexa, patients with AT and treated with EryDex n = 10;
WT, healthy volunteers n = 6. As predicted, in treated AT patients an
improvement in gene expression was observed
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reported by Savitsky et al. [24] regarding the possibility
of alternative splicing of ATM mRNA, we were able to
discover and report an alternative splicing event within
the coding sequence of the ATM gene product. In fact,
we have shown, in lymphoblastoid cell lines established
from AT patients, that the action of the synthetic GC
Dexamethasone may also be exerted through the
assembly of a new mRNA molecule generated by a
non-canonical splicing of the ATM gene. The resulting
transcript, designated as ATMdexa1, has also been
identified “in vivo” in the blood of AT patients receiving
intra-erythrocyte Dexamethasone. The identified splicing
procedure is an SDR (short direct repeat) mediated
joining, an occurrence described in plants as an environ-
mental stress defense mechanism [25–27]. In mammals,
this occurrence has only been described as aberrant and
nonfunctional splicing [28, 29] while to our knowledge,
the splicing involved in ATMdexa1 assembly represents
the only reported case of functional non-canonical SDR
splicing.
ATMdexa1 transcript expression levels depend on the
treatment with Dexamethasone since, neither untreated
AT patients nor untreated healthy volunteers showed
detectable levels of the transcript, and its levels are par-
tially correlated with the amount of the administered
drug. This correlation was observed in two of the avail-
able samples in a time dependent manner. Of consider-
able interest are the differences in ATMdexa1 expression
levels between the two clusters of patients, responders
and non-responders. Indeed, on average, responders
showed higher levels than non-responders. In light of
the fact that the expression of genes such as FKBP5 and
DUSP1 are known to be induced by glucocorticoid treat-
ment, ATMdexa1 (miniATM RNA) may be a potential
Fig. 4 ATMdexa1 transcript family. Amplicons obtained by 5′ nuclease qPCR of the compassionate EryDex samples analysed by electrophoretic
gel. Lane M, DNA ladder. Lanes 1–16 contain the qPCR products from five patient samples collected at different time points. The white arrows
show the ATMdexa1 PCR product, while the amplicon in all lanes at 115 bp is the HPRT1 PCR product. The other PCR products, with the
exception of non-specific amplicons, represent ATMdexa1 splicing variants: green arrow splicing SDR 4–51; yellow arrows splicing 4–53; red ar-
rows splicing 3–52; cyan arrow splicing SDR 3–52 and magenta arrow splicing 2–52
Fig. 5 Schematic of the ATMdaxa1 transcripts family. Five ATMdexa1 variants were characterised. Three components of the family derived from
canonical splicing while two were from an SDR mediated splicing
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molecular blood marker to gauge treatment efficacy and
predict outcome in AT patients. Additional studies with
larger sample pools are needed to confirm this
hypothesis.
The analysis of the transcripts in additional samples
from patients undergoing compassionate treatment with
EryDex [19] revealed the existence of not only ATM-
dexa1 but also of an ATMdexa1 transcript family, de-
tectable by the designed qPCR assays. Unlike the known
transcript (ATMdexa1), the transcripts of the new family
are formed also by a canonical splicing occurrence.
It is possible to speculate that all these shortened
ATM transcripts are latent in human genomics [30]
and that Dexa may simply turn on a switch in AT
patients to activate a rescue program by multiple
ATMdexa1 transcripts potentially translatable into
miniATM proteins. The probability of latent and in-
ducible splicing has been extensively investigated in
genomic studies [31], and the use of exon skipping is
an established strategy in some severe diseases such
as Duchenne muscular dystrophy [32]. Currently we
have no data on the presence of these shorter tran-
scripts in other cell lines or tissues, but the detection
of the ATMdexa1 family in vivo suggests that a simi-
lar response may occur in other organs.
Conclusions
This investigation has shown that the ATMdexa1
transcript is detectable in the whole blood of AT pa-
tients treated with EryDex. The expression levels of
the transcript were found to depend on drug adminis-
tration and time from drug infusion, and to correlate
with the patients’ responsiveness to treatment. Hence,
the detection of the ATMdexa1 transcript may repre-
sent a molecular marker that could be used as a
prognostic marker to gauge drug effectiveness.
Additional clinical trials are needed to further test
these hypotheses. In the present study we also de-
scribe for the first time the presence of an ATMdexa1
transcript family composed of multiple splicing forms
of ATM mRNA, similar to ATMdexa1, and potentially
translatable in the miniATM protein. These findings
call for additional studies on the role of the multipli-
city molecular forms of ATM transcripts induced by
Dexamethasone in Ataxia Telangiectasia patients.
Additional file
Additional file 1: Figure S1. Melting analysis of IEDAT qPCR amplicons.
During SYBR green qPCR of the IEDAT samples, although only one PCR
product was observable by melting step at the end of the experimental,
some Tm discrepancies were noted among the samples. A different kind
of ATMdexa1 target was probably amplified without affecting the PCR
performance. (TIFF 41 kb)
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